// App-Quantinova.ai

9062.0 : Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.

Researchers

Presenter

  • Corey Carter

Principal Investigators

  • Yusuke Tomita

  • Akira Yuno

  • Jonathan Baker

  • Min-Jung Lee

  • Sunmin Lee

  • Scott Caroen

  • Mary Flanagan Quinn

  • Bryan Oronsky

  • Tony R. Reid

  • Pedro Cabrales

  • Nacer Abrouk

  • Jane B Trepel

Medical Centers

  • EpicentRx, Torrey Pines, CA

  • CCR, NIH, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • EpicentRx, Inc., Mountain View, CA.

  • Natoinal Naval Medical Center, Rockville, MD

  • UCSD, La Jolla, CA

  • Innovexe, Inc, Mountain View, CA

  • Center for Cancer Research, NCI, NIH, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 47

  • Programmed death-ligand 1

Drug/Treatment

  • RRx001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02489903

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved